Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB01323"

Predicate	Value (sorted: default)
rdfs:label	"St. John's Wort"
rdf:type	drugbank:drugs
drugbank:description	" nutraceutical # Lecrubier Y, Clerc G, Didi R, Kieser M: Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12153829 # Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K: The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine. 2006 Mar;13(4):215-21. Epub 2006 Jan 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16423519 # : Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 Apr 10;287(14):1807-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11939866 Trevor Percival Castor, Theodore Abraham Tyler, Richard Joseph Student, "Methods for making Hypericum fractions and St. John's Wort products." U.S. Patent US6291241, issued December, 1998. Guna Inc. http://www.gunainc.com Pekana Naturheilmittel GmbH http://www.pekana.com Weleda Inc. http://www.weleda.com DB00404 Alprazolam St. John's Wort may decrease the effect of the benzodiazepine, alprazolam. DB01223 Aminophylline St. John's Wort decreases the effect of theophylline DB00701 Amprenavir St. John's Wort decreases the effect of indinavir DB01072 Atazanavir St. John's Wort decreases the levels/effects of atazanavir DB06626 Axitinib Avoid combination due to the likely decreased levels of axitinib. DB08873 Boceprevir Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. DB06772 Cabazitaxel Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. DB08875 Cabozantinib Avoid combination. May decrease concentration of cabozantinib. Also avoid all other strong CYP3A4 inducers. DB00215 Citalopram St. John's Wort increases the effect and toxicity of the SSRI, citalopram. DB01068 Clonazepam St. John's Wort may decrease the effect of the benzodiazepine, clonazepam. DB00091 Cyclosporine St. John's Wort decreases the effect of cyclosporine DB00705 Delavirdine St. John's Wort decreases the antiretroviral effect DB06700 Desvenlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. DB00829 Diazepam St. John's Wort may decrease the effect of the benzodiazepine, diazepam. DB00390 Digoxin St. John's Wort decreases the effect of digoxin DB00625 Efavirenz St. John's Wort decreases the antiretroviral effect DB00530 Erlotinib Decreased levels/effect of erlotinib DB01175 Escitalopram St. John's Wort increases the effect and toxicity of the SSRI, escitalopram. DB08866 Estradiol valerate/Dienogest Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest. DB00977 Ethinyl Estradiol St. John's Wort could reduce the contraceptive effect DB06414 Etravirine Etravirine may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy. DB00472 Fluoxetine St. John's Wort increases the effect and toxicity of the SSRI, fluoxetine. DB00176 Fluvoxamine St. John's Wort increases the effect and toxicity of the SSRI, fluvoxamine. DB01319 Fosamprenavir St. John's Wort decreases the effect of indinavir DB00317 Gefitinib The CYP3A4 inducer, St. John's Wort, may decrease the serum concentration and therapeutic effects of gefitinib. DB00619 Imatinib St. John's Wort decreases levels of imatinib DB00224 Indinavir St. John's Wort decreases the effect of indinavir DB08820 Ivacaftor Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. DB00333 Methadone St. John's Wort decreases levels/effect of methadone DB00683 Midazolam St. John's Wort may decrease the effect of the benzodiazepine, midazolam. DB01149 Nefazodone St. John's Wort increases the effect and toxicity of the SSRI, nefazodone. DB00220 Nelfinavir St. John's Wort decreases the effect of indinavir DB00238 Nevirapine St. John's Wort decreases nevirapine effect DB01115 Nifedipine St. John's Wort decreases the effect of nifedipine DB00717 Norethindrone St. John's Wort could reduce the contraceptive effect DB00338 Omeprazole St. John's Wort decreases the levels/effects of omeprazole DB01303 Oxtriphylline St. John's Wort decreases the effect of theophylline DB01229 Paclitaxel Avoid combination due to potential decrease in serum concentration of paclitaxel. DB00715 Paroxetine St. John's Wort increases the effect and toxicity of the SSRI, paroxetine. DB08883 Perampanel Avoid combination due to the potential decrease in perampanel concentration. DB01367 Rasagiline Increased risk of toxicity with this association DB08896 Regorafenib Strong CYP3A4 inducers may decrease levels of regorafenib. DB01656 Roflumilast Affects CYP3A4 metabolism, decreases level or effect of roflumilast. DB00864 Tacrolimus St. John's Wort may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if St. John's Wort therapy is initiated, discontinued or altered. DB06287 Temsirolimus St. John's Wort may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided. DB00277 Theophylline St. John's Wort decreases the effect of theophylline DB00932 Tipranavir St. John's Wort may decrease the concentration and efficacy of Tipranavir. Concomitant therapy should be avoided. DB06212 Tolvaptan St. John's Wort is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. DB00193 Tramadol Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. DB00752 Tranylcypromine Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. DB00656 Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. DB00897 Triazolam St. John's Wort may decrease the effect of the benzodiazepine, triazolam. DB00726 Trimipramine St. John's Wort may decrease serum concentrations of Trimipramine. Possible increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if St. John's Wort is initiated, discontinued or dose changed. DB08867 Ulipristal Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. DB05294 Vandetanib Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated. DB00285 Venlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. DB00582 Voriconazole St. John's Wort may decrease the serum concentration of voriconazole by increasing its elimination. Concomitant therapy is contraindicated. DB00682 Warfarin St. John's Wort may decrease the serum concentration of warfarin by increasing its metabolism. Concomitant therapy should be avoided. Monitor for changes in the therapeutic and adverse effects of warfarin if St. John's Wort is initiated, discontinued or dose changed. DB00315 Zolmitriptan Use of two serotonin modulators, such as zolmitriptan and St. John's Wort, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. Drugs Product Database (DPD) 2119897 PharmGKB PA164924486 Wikipedia St_John%27s_wort Drugs.com http://www.drugs.com/cdi/st-john-s-wort.html BE0001032 Multidrug resistance protein 1 Human inducer # Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000 Dec;68(6):598-604. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11180019 unknown Multidrug resistance protein 1 Defense mechanisms and drug export Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells ABCB1 7q21.1 Membrane; multi-pass membrane protein 52-72 120-140 189-209 216-236 297-317 326-346 711-731 757-777 833-853 854-874 937-957 974-994 9.44 141464.0 Human HUGO Gene Nomenclature Committee (HGNC) HGNC:40 GenAtlas ABCB1 GeneCards ABCB1 GenBank Gene Database M14758 GenBank Protein Database 307180 UniProtKB P08183 UniProt Accession MDR1_HUMAN ATP-binding cassette sub-family B member 1 CD243 antigen EC 3.6.3.44 P-glycoprotein 1 >Multidrug resistance protein 1 MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGAGKIATEA IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL LAQKGIYFSMVSVQAGTKRQ >3843 bp ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCT AAGATTAATGAAGTTATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGCCTGAACCTGAAGGTGCAGAGTGGG CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTGCTGGGAAGATCGCTACTGAAGCA ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG TCACAGGAAGAGATCGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG TGA PF00005 ABC_tran PF00664 ABC_membrane component cell component intrinsic to membrane component integral to membrane component membrane function catalytic activity function hydrolase activity, acting on acid anhydrides function hydrolase activity function hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides function nucleotide binding function pyrophosphatase activity function purine nucleotide binding function nucleoside-triphosphatase activity function adenyl nucleotide binding function ATPase activity function hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances function ATPase activity, coupled to transmembrane movement of substances function binding function ATP binding process transport process physiological process process cellular physiological process "
drugbank:interactsWith	drug:Cyclosporine drug:Fluvoxamine drug:Tramadol drug:Citalopram drug:Nelfinavir drug:Indinavir drug:Nevirapine drug:Theophylline drug:Venlafaxine drug:Zolmitriptan drug:Gefitinib drug:Methadone drug:Omeprazole drug:Digoxin drug:Alprazolam drug:Fluoxetine drug:Erlotinib drug:Voriconazole drug:Imatinib drug:Efavirenz drug:Trazodone drug:Warfarin drug:Midazolam drug:Amprenavir drug:Delavirdine drug:Paroxetine drug:Norethindrone drug:Trimipramine drug:Tranylcypromine drug:Diazepam drug:Tacrolimus drug:Triazolam drug:Tipranavir drug:Ethinyl Estradiol drug:Clonazepam drug:Atazanavir drug:Nifedipine drug:Nefazodone drug:Escitalopram drug:Aminophylline drug:Paclitaxel drug:Oxtriphylline drug:Fosamprenavir drug:Rasagiline drug:Roflumilast drug:Vandetanib drug:Tolvaptan drug:Temsirolimus drug:Etravirine drug:Axitinib drug:Desvenlafaxine drug:Cabazitaxel drug:Ivacaftor drug:Estradiol valerate/Dienogest drug:DB08867 drug:Boceprevir drug:Cabozantinib drug:Perampanel drug:Regorafenib
owl:sameAs	drug:Cyclosporine drug:Fluvoxamine drug:Tramadol drug:Citalopram drug:Nelfinavir drug:Indinavir drug:Nevirapine drug:Theophylline drug:Venlafaxine drug:Zolmitriptan drug:Gefitinib drug:Methadone drug:Omeprazole drug:Digoxin drug:Alprazolam drug:Fluoxetine drug:Erlotinib drug:Voriconazole drug:Imatinib drug:Efavirenz drug:Trazodone drug:Warfarin drug:Midazolam drug:Amprenavir drug:Delavirdine drug:Paroxetine drug:Norethindrone drug:Trimipramine drug:Tranylcypromine drug:Diazepam drug:Tacrolimus drug:Triazolam drug:Tipranavir drug:Ethinyl Estradiol drug:Clonazepam drug:Atazanavir drug:Nifedipine drug:Nefazodone drug:Escitalopram drug:Aminophylline drug:Paclitaxel drug:Oxtriphylline drug:Fosamprenavir drug:Rasagiline drug:Roflumilast drug:Vandetanib drug:Tolvaptan drug:Temsirolimus drug:Etravirine drug:Axitinib drug:Desvenlafaxine drug:Cabazitaxel drug:Ivacaftor drug:Estradiol valerate/Dienogest drug:DB08867 drug:Boceprevir drug:Cabozantinib drug:Perampanel drug:Regorafenib

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines3/drugbank_small.nt

The resource appears as object in 117 triples

Context graph